SEC Comment Letter for Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Apr 8, 2019
Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: April 8, 2019 · CIK: 0001006281 · Accession: 0000000000-19-006718
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230604
Letter
April 5, 2019 Moshe Manor President and Chief Executive Officer Protalix BioTherapeutics, Inc. 2 Snunit Street Science Park P.O. Box 455 Carmiel, Israel 20100 Re:Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 Filed March 29, 2019 File No. 333-230604 Dear Mr. Manor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joseph McCann at (202) 551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
April 5, 2019
Moshe Manor
President and Chief Executive Officer
Protalix BioTherapeutics, Inc.
2 Snunit Street
Science Park
P.O. Box 455
Carmiel, Israel 20100
Re:Protalix BioTherapeutics, Inc.
Registration Statement on Form S-3
Filed March 29, 2019
File No. 333-230604
Dear Mr. Manor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joseph McCann at (202) 551-6262 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance